Abstract
Across the pharmaceutical industry, there is increasing interest and need to investigate the biotransformation of oligonucleotide drugs. The method of choice is high-resolution mass spectrometry due to its unmet sensitivity and specificity.
Here, we describe a method developed and applied in our laboratory studying the biotransformation of phosphorothioate-containing oligonucleotide drugs. This method is based on capillary flow liquid chromatography with column switching coupled to high-resolution mass spectrometry.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Husser C, Brink A, Zell M, Muller MB, Koller E, Schadt S (2017) Identification of GalNAc-conjugated antisense oligonucleotide metabolites using an untargeted and generic approach based on high resolution mass spectrometry. Anal Chem 89(12):6821–6826. https://doi.org/10.1021/acs.analchem.7b01244
Shemesh CS, Yu RZ, Gaus HJ, Greenlee S, Post N, Schmidt K, Migawa MT, Seth PP, Zanardi TA, Prakash TP, Swayze EE, Henry SP, Wang Y (2016) Elucidation of the biotransformation pathways of a Galnac3-conjugated antisense oligonucleotide in rats and monkeys. Mol Ther Nucleic Acids 5:e319. https://doi.org/10.1038/mtna.2016.31
Crooke ST (2008) Antisense drug technology: principles, strategies, and applications, 2nd edn. CRC Press, Boca Raton
Yu RZ, Kim TW, Hong A, Watanabe TA, Gaus HJ, Geary RS (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35(3):460–468. https://doi.org/10.1124/dmd.106.012401
Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46–51. https://doi.org/10.1016/j.addr.2015.01.008
Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5(4):381–391. https://doi.org/10.1517/17425250902877680
Yu RZ, Grundy JS, Geary RS (2013) Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9(2):169–182. https://doi.org/10.1517/17425255.2013.737320
Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44(14):6518–6548. https://doi.org/10.1093/nar/gkw236
Frieden M, Hansen HF, Koch T (2003) Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras. Nucleosides Nucleotides Nucleic Acids 22(5-8):1041–1043. https://doi.org/10.1081/NCN-120022731
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Husser, C., Koller, E., Brink, A., Schadt, S. (2019). Studying the Biotransformation of Phosphorothioate-Containing Oligonucleotide Drugs by LC-MS. In: Gissberg, O., Zain, R., Lundin, K. (eds) Oligonucleotide-Based Therapies. Methods in Molecular Biology, vol 2036. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9670-4_18
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9670-4_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9669-8
Online ISBN: 978-1-4939-9670-4
eBook Packages: Springer Protocols